Published in J Virol on October 29, 2008
Coordinated regulation of SIV replication and immune responses in the CNS. PLoS One (2009) 1.49
H5N1 influenza virus pathogenesis in genetically diverse mice is mediated at the level of viral load. MBio (2011) 1.22
Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine (2009) 1.14
Cytokine determinants of viral tropism. Nat Rev Immunol (2009) 1.10
Inhibition of HIV-1 particle assembly by 2',3'-cyclic-nucleotide 3'-phosphodiesterase. Cell Host Microbe (2012) 1.09
Rotavirus antagonizes cellular antiviral responses by inhibiting the nuclear accumulation of STAT1, STAT2, and NF-kappaB. J Virol (2009) 1.08
Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev (2010) 1.06
The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics. Microbes Infect (2010) 1.03
STAT2 and IRF9: Beyond ISGF3. JAKSTAT (2013) 1.01
Oncolytic Poxviruses. Annu Rev Virol (2014) 0.96
Oncolytic myxoma virus: the path to clinic. Vaccine (2013) 0.95
An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection. J Virol (2012) 0.94
Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology (2010) 0.93
Myxoma and vaccinia viruses bind differentially to human leukocytes. J Virol (2013) 0.90
IFNβ/TNFα synergism induces a non-canonical STAT2/IRF9-dependent pathway triggering a novel DUOX2 NADPH oxidase-mediated airway antiviral response. Cell Res (2013) 0.90
The current status and future directions of myxoma virus, a master in immune evasion. Vet Res (2011) 0.90
Oncolytic virotherapy of canine and feline cancer. Viruses (2014) 0.89
Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro Oncol (2013) 0.87
SAMD9 is an innate antiviral host factor with stress response properties that can be antagonized by poxviruses. J Virol (2014) 0.87
Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells. PLoS One (2013) 0.84
Cytokine synergy: an underappreciated contributor to innate anti-viral immunity. Cytokine (2013) 0.83
Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. Blood (2015) 0.82
RIG-I-Mediated STING Upregulation Restricts Herpes Simplex Virus 1 Infection. J Virol (2016) 0.79
Convergent Transcription of Interferon-stimulated Genes by TNF-α and IFN-α Augments Antiviral Activity against HCV and HEV. Sci Rep (2016) 0.77
Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. Oncotarget (2016) 0.75
Constitutive IFNα/β signaling maintains expression of signaling intermediaries for efficient cytokine responses. JAKSTAT (2016) 0.75
Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor. Mol Ther Oncolytics (2016) 0.75
Vaccinia reporter viruses for quantifying viral function at all stages of gene expression. J Vis Exp (2014) 0.75
Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice. Mol Ther Oncolytics (2016) 0.75
Novel antiviral activity of mung bean sprouts against respiratory syncytial virus and herpes simplex virus -1: an in vitro study on virally infected Vero and MRC-5 cell lines. BMC Complement Altern Med (2015) 0.75
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma. Oncolytic Virother (2015) 0.75
Myxoma Virus dsRNA Binding Protein M029 Inhibits the Type I IFN-Induced Antiviral State in a Highly Species-Specific Fashion. Viruses (2017) 0.75
Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. Viruses (2016) 0.75
Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model. Mol Ther Oncolytics (2017) 0.75
Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A (2001) 68.44
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
Antiviral actions of interferons. Clin Microbiol Rev (2001) 13.06
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 4.98
The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol (2005) 4.83
Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature (1986) 4.81
Poxviruses and immune evasion. Annu Rev Immunol (2001) 4.80
Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer (2003) 3.23
Poxvirus tropism. Nat Rev Microbiol (2005) 3.07
Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol (2004) 2.51
Human monkeypox: an emerging zoonotic disease. Future Microbiol (2007) 2.15
Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. Virology (1999) 2.02
Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor. J Gen Virol (1994) 1.89
Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus. J Virol (1989) 1.71
Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol (2003) 1.69
Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J Virol (2002) 1.65
Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther (2007) 1.63
Zoonotic poxvirus infections in humans. Curr Opin Infect Dis (2004) 1.58
Gene expression profiling of the cellular transcriptional network regulated by alpha/beta interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein. J Virol (2003) 1.56
Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet Res (2007) 1.55
Activity of rat Mx proteins against a rhabdovirus. J Virol (1990) 1.52
Immune responses to myxoma virus. Viral Immunol (2002) 1.50
RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog (2008) 1.49
Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol (2006) 1.44
Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro. J Virol (1996) 1.40
Tumor necrosis factor acts synergistically with autocrine interferon-beta and increases interferon-beta mRNA levels in human fibroblasts. J Biol Chem (1989) 1.37
An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter. J Virol (1998) 1.35
Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays. J Virol Methods (2001) 1.27
Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2',5'-adenylate synthetase. J Gen Virol (1988) 1.26
Inhibition of VSV and EMCV replication by the interferon-induced GTPase, mGBP-2: differential requirement for wild-type GTP binding domain. Arch Virol (2005) 1.22
Mouse Mx2 protein inhibits vesicular stomatitis virus but not influenza virus. Virology (1992) 1.17
Differential gamma-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effects of gamma-interferon on tumor cell growth. Cancer Res (1985) 1.11
Tumor necrosis factor and interferon: cytokines in harmony. Curr Opin Microbiol (2008) 1.08
LIF-induced STAT3 signaling in murine versus human embryonal carcinoma (EC) cells. Exp Cell Res (2002) 1.07
Microarray analysis of tumor necrosis factor alpha induced gene expression in U373 human glioblastoma cells. BMC Genomics (2003) 1.05
Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma. Virol J (2005) 1.04
Indoleamine 2,3-dioxygenase mediates cell type-specific anti-measles virus activity of gamma interferon. J Virol (2005) 1.03
Antimicrobial and immunoregulatory effects mediated by human lung cells: role of IFN-gamma-induced tryptophan degradation. FEMS Immunol Med Microbiol (2008) 1.00
Role of the protein kinase PKR in the inhibition of varicella-zoster virus replication by beta interferon and gamma interferon. J Gen Virol (2005) 1.00
Independent and cooperative antiviral actions of beta interferon and gamma interferon against herpes simplex virus replication in primary human fibroblasts. J Virol (2007) 0.96
Human T-cell leukemia virus type 1 oncoprotein tax represses ZNF268 expression through the cAMP-responsive element-binding protein/activating transcription factor pathway. J Biol Chem (2008) 0.95
Role of human brain microvascular endothelial cells during central nervous system infection. Significance of indoleamine 2,3-dioxygenase in antimicrobial defence and immunoregulation. Thromb Haemost (2005) 0.89
Interferon-gamma-induced assembly block in the replication cycle of adenovirus 2: augmentation by tumour necrosis factor-alpha. Virology (1992) 0.88
Shear stress regulates gene expression in vascular endothelial cells in response to tumor necrosis factor-alpha: a study of the transcription profile with complementary DNA microarray. J Biomed Sci (2005) 0.87
Synergistic inhibition of pseudorabies virus replication by porcine alpha/beta interferon and gamma interferon in vitro. Eur Cytokine Netw (2007) 0.86
ATF/CREB elements in the herpes simplex virus type 1 latency-associated transcript promoter interact with members of the ATF/CREB and AP-1 transcription factor families. J Biomed Sci (1999) 0.86
Synergy of antiviral actions of TNF and IFN-gamma: evidence for a major role of TNF-induced IFN-beta. Antiviral Res (1988) 0.84
Tropism of Tanapox virus infection in primary human cells. Virology (2007) 0.83
Expression profiling and interferon-beta regulation of liver metastases in colorectal cancer cells. Clin Exp Metastasis (2002) 0.82
The in vitro antiviral activity of tumor necrosis factor (TNF) in WISH cells is mediated by IFN-beta induction. Antiviral Res (1989) 0.80
The synergistic effect of IFN-alpha and IFN-gamma against HSV-2 replication in Vero cells is not interfered by the plant antiviral 1-cinnamoyl-3, 11-dihydroxymeliacarpin. Virol J (2006) 0.78
Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A (2013) 16.74
A network-based analysis of systemic inflammation in humans. Nature (2005) 12.60
A genomic storm in critically injured humans. J Exp Med (2011) 6.67
Poxviruses and immune evasion. Annu Rev Immunol (2001) 4.80
Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J Virol (2007) 4.19
Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell (2006) 3.83
Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A (2005) 3.49
A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. Immunity (2005) 3.43
Whole blood and leukocyte RNA isolation for gene expression analyses. Physiol Genomics (2004) 3.22
Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog (2007) 3.16
Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol (2004) 2.51
Different roles of EIIABMan and EIIGlc in regulation of energy metabolism, biofilm development, and competence in Streptococcus mutans. J Bacteriol (2006) 2.00
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A (2006) 1.96
Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients. Crit Care Med (2013) 1.94
Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proc Natl Acad Sci U S A (2006) 1.82
Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria. Infect Immun (2003) 1.75
Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol (2003) 1.69
Modulation of NF-κB signalling by microbial pathogens. Nat Rev Microbiol (2011) 1.64
Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther (2007) 1.63
A better understanding of why murine models of trauma do not recapitulate the human syndrome. Crit Care Med (2014) 1.62
ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer (2008) 1.56
Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet Res (2007) 1.55
Smallpox: anything to declare? Nat Rev Immunol (2002) 1.53
Poxvirus immunomodulatory strategies: current perspectives. J Virol (2003) 1.52
The PHD/LAP-domain protein M153R of myxomavirus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4. J Virol (2003) 1.52
Distinct transcriptional profiles characterize oral epithelium-microbiota interactions. Cell Microbiol (2005) 1.51
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res (2007) 1.50
Immune responses to myxoma virus. Viral Immunol (2002) 1.50
RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog (2008) 1.49
Gingival epithelial cell transcriptional responses to commensal and opportunistic oral microbial species. Infect Immun (2007) 1.44
Influence of BrpA on critical virulence attributes of Streptococcus mutans. J Bacteriol (2006) 1.42
Commonality and differences in leukocyte gene expression patterns among three models of inflammation and injury. Physiol Genomics (2005) 1.40
When good vaccines go wild: Feral Orthopoxvirus in developing countries and beyond. J Infect Dev Ctries (2008) 1.40
The myxoma poxvirus protein, M11L, prevents apoptosis by direct interaction with the mitochondrial permeability transition pore. J Exp Med (2002) 1.39
Modulation of tumor necrosis factor by microbial pathogens. PLoS Pathog (2006) 1.34
Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe (2013) 1.33
Analysis of factorial time-course microarrays with application to a clinical study of burn injury. Proc Natl Acad Sci U S A (2010) 1.33
Co-regulation of NF-kappaB and inflammasome-mediated inflammatory responses by myxoma virus pyrin domain-containing protein M013. PLoS Pathog (2009) 1.32
Comparison of longitudinal leukocyte gene expression after burn injury or trauma-hemorrhage in mice. Physiol Genomics (2007) 1.30
Myxoma virus: propagation, purification, quantification, and storage. Curr Protoc Microbiol (2010) 1.29
MucA-mediated coordination of type III secretion and alginate synthesis in Pseudomonas aeruginosa. J Bacteriol (2004) 1.29
Incidence, clinical predictors, genomics, and outcome of acute kidney injury among trauma patients. Ann Surg (2010) 1.27
Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak. J Virol (2004) 1.27
An in vivo inducible gene of Pseudomonas aeruginosa encodes an anti-ExsA to suppress the type III secretion system. Mol Microbiol (2004) 1.26
Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol (2006) 1.25
Microarray analysis of A549 cells infected with rabbitpox virus (RPV): a comparison of wild-type RPV and RPV deleted for the host range gene, SPI-1. Virology (2003) 1.23
Poxvirus host range genes. Adv Virus Res (2008) 1.23
Severe injury is associated with insulin resistance, endoplasmic reticulum stress response, and unfolded protein response. Ann Surg (2012) 1.21
Role of Porphyromonas gingivalis SerB in gingival epithelial cell cytoskeletal remodeling and cytokine production. Infect Immun (2008) 1.21
Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. J Virol (2005) 1.20
NFkB inhibitors: strategies from poxviruses. Cell Cycle (2009) 1.18
Poxviruses and apoptosis: a time to die. Curr Opin Microbiol (2002) 1.17
Ultrasensitive detection of biomolecules with fluorescent dye-doped nanoparticles. Anal Biochem (2004) 1.17
Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol (2004) 1.16
Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther (2007) 1.16
Expression profiling after activation of amino acid deprivation response in HepG2 human hepatoma cells. Physiol Genomics (2010) 1.15
Changes in transcription within the CA1 field of the hippocampus are associated with age-related spatial learning impairments. Neurobiol Learn Mem (2006) 1.14
Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine (2009) 1.14
Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther (2009) 1.13
Viral chemokine-binding proteins. J Leukoc Biol (2002) 1.13
Secreted immunomodulatory viral proteins as novel biotherapeutics. J Immunol (2004) 1.13
M062 is a host range factor essential for myxoma virus pathogenesis and functions as an antagonist of host SAMD9 in human cells. J Virol (2011) 1.13
Patterns of gene expression reveal a temporally orchestrated wound healing response in the injured spinal cord. J Neurosci (2004) 1.13
Flagellin enhances NK cell proliferation and activation directly and through dendritic cell-NK cell interactions. J Leukoc Biol (2005) 1.12
Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses. Proc Natl Acad Sci U S A (2009) 1.11
Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2. Protein Sci (2007) 1.11
Cytokine determinants of viral tropism. Nat Rev Immunol (2009) 1.10
The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus. Biochim Biophys Acta (2007) 1.09
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res (2008) 1.08
Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol Cell Biol (2007) 1.08
Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res (2010) 1.08
Tumor necrosis factor and interferon: cytokines in harmony. Curr Opin Microbiol (2008) 1.08
Analysis of vaccinia virus-host protein-protein interactions: validations of yeast two-hybrid screenings. J Proteome Res (2009) 1.07
Voluntary exercise prevents the obese and diabetic metabolic syndrome of the melanocortin-4 receptor knockout mouse. FASEB J (2008) 1.06
Persistent inflammation, immunosuppression, and catabolism syndrome after severe blunt trauma. J Trauma Acute Care Surg (2014) 1.06
Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev (2010) 1.06
Genomic and proteomic determinants of outcome in patients undergoing thoracoabdominal aortic aneurysm repair. J Immunol (2004) 1.06
Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria. J Virol (2006) 1.06
Myxoma virus M128L is expressed as a cell surface CD47-like virulence factor that contributes to the downregulation of macrophage activation in vivo. Virology (2005) 1.06
Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J Neurovirol (2007) 1.06
Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann Surg Oncol (2008) 1.06
Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant (2012) 1.06
M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. J Virol (2006) 1.05
Complete genomic sequence and comparative analysis of the tumorigenic poxvirus Yaba monkey tumor virus. J Virol (2003) 1.05
Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells. J Nutr (2006) 1.05
Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. J Virol (2009) 1.04
Roles of vaccinia virus genes E3L and K3L and host genes PKR and RNase L during intratracheal infection of C57BL/6 mice. J Virol (2010) 1.04